Xencor is trading at $24.50, down 5.21%, alongside weakness across biotech stocks.
- XBI is down 2.08% during the session, while broader markets are also weak.
- Xencor’s announced XmAb819 kidney-cancer data are being presented at ESMO, with a company webcast scheduled for October 26; this does not establish a reason for the decline.
- Intraday volume information was unavailable.